Advertisement
Research Article

Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant

  • Javier Guenaga,

    Affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America

    Current address: IAVI Neutralizing Antibody Center at The Scripps Research Institute (TSRI), La Jolla, California, United States of America

    X
  • Pia Dosenovic,

    Affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

    X
  • Gilad Ofek,

    Affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • David Baker,

    Affiliation: University of Washington, Seattle, Washington, United States of America

    X
  • William R. Schief,

    Affiliation: University of Washington, Seattle, Washington, United States of America

    X
  • Peter D. Kwong,

    Affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Gunilla B. Karlsson Hedestam,

    Affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

    X
  • Richard T. Wyatt mail

    wyatt@scripps.edu

    Affiliation: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America

    Current address: IAVI Neutralizing Antibody Center at The Scripps Research Institute (TSRI), La Jolla, California, United States of America

    X
  • Published: January 26, 2011
  • DOI: 10.1371/journal.pone.0016074

Reader Comments (0)

Post a new comment on this article